Prolactinomas are the most common type of hormone-producing pituitary tumor, with an estimated prevalence of about 50 per 100,000 people. That translates to roughly 1 in 2,000 adults walking around with one, though many never know it. Each year, 3 to 5 new cases per 100,000 people are diagnosed.
How Prolactinomas Compare to Other Pituitary Tumors
Pituitary tumors as a whole are surprisingly common. Autopsy studies find pituitary adenomas in about 10.6% of people who died of unrelated causes, and brain scans done for other reasons pick up small pituitary growths in 10 to 38% of adults on MRI. Most of these are tiny, produce no symptoms, and would never have been found without the scan.
Among pituitary tumors that do get diagnosed, prolactinomas are the single largest category of functioning (hormone-producing) tumors. In a large pathology study, prolactin-producing tumors made up about 28% of all tumors in the growth-hormone-related lineage of pituitary cells. What makes that number particularly notable is that many small prolactinomas go undetected entirely. In one large autopsy study, 39.5% of incidentally discovered pituitary adenomas stained positive for prolactin, meaning they were quietly producing the hormone without ever causing noticeable problems during the person’s lifetime.
Who Gets Prolactinomas
Prolactinomas overwhelmingly favor women of reproductive age. In women between 20 and 50, the female-to-male ratio is approximately 10 to 1. This isn’t just a detection bias from women noticing menstrual irregularities sooner. Research suggests that estrogen receptor pathways play a genuine role in how these tumors develop and behave, which helps explain the dramatic sex difference.
After menopause, the gap between men and women narrows considerably. Men can and do develop prolactinomas, but their tumors tend to behave differently. About 60% of men with prolactinomas present with macroprolactinomas (tumors 10 millimeters or larger), while 90% of women present with microprolactinomas (under 10 millimeters). Men also tend to be older at diagnosis and have higher prolactin levels. This size difference doesn’t appear to be simply because men wait longer to seek care. Studies comparing tumor biology between the sexes suggest that tumors in men genuinely grow more aggressively, likely driven by differences in hormone signaling rather than diagnostic delay alone.
Prolactinomas in Children and Teens
Prolactinomas are rare in the pediatric population. The estimated incidence is less than 0.1 case per million children per year, making them fewer than 2% of all childhood intracranial tumors. One regional study tracking diagnoses over nearly two decades found a slightly higher rate of 0.29 cases per million per year, but even that figure underscores how uncommon these tumors are before adulthood. When prolactinomas do occur in adolescents, they most often show up around puberty, when hormonal shifts can unmask symptoms or accelerate tumor growth.
Racial and Ethnic Differences
Not everyone faces the same risk. A large U.S. study examining pituitary adenoma incidence across racial groups found significant disparities. Black Americans had an age-adjusted incidence rate of 4.4 per 100,000 for pituitary adenomas overall, compared to 2.5 for white Americans, 2.3 for Asian/Pacific Islander Americans, and 1.9 for American Indian/Alaska Native populations. The higher rate among Black Americans has been a consistent finding across decades and different geographic regions, and data from African populations shows a similar pattern, suggesting a biological component rather than a simple artifact of healthcare access. These figures cover all pituitary adenomas, not prolactinomas specifically, but since prolactinomas are the most common functioning subtype, they likely account for a meaningful share of the difference.
Many Prolactinomas Go Undiagnosed
The 50 per 100,000 prevalence figure represents diagnosed cases. The true number is almost certainly higher. Autopsy and imaging data make this clear: when researchers look at pituitary glands from people who had no known pituitary disease, they find adenomas at rates far above what clinical diagnosis would predict. In one study of patients with incidentally discovered pituitary growths, prolactinomas were identified in about 15% of those evaluated further (7 out of 46). Among incidental microadenomas specifically, roughly 12% had elevated prolactin at their first evaluation.
Small prolactinomas that produce only mild elevations in prolactin can cause subtle symptoms, things like slightly irregular periods, mild fatigue, or reduced sex drive, that many people chalk up to stress or aging. In men especially, where the classic symptom is a gradual decline in libido and energy, the tumor can grow for years before anyone thinks to check prolactin levels. This is a key reason why men tend to be diagnosed later and with larger tumors.
Microprolactinomas vs. Macroprolactinomas
The size of the tumor at diagnosis matters for treatment and outlook. Microprolactinomas (under 10 mm) are far more common overall, largely because of the high proportion of young women diagnosed with them. These smaller tumors respond well to medication that lowers prolactin levels and often shrinks the tumor. Many microprolactinomas remain stable for years without growing, and some eventually become inactive on their own.
Macroprolactinomas (10 mm or larger) are less common but more clinically significant. They can press on nearby structures like the optic nerves, causing vision changes, or invade surrounding tissue. They still respond to the same class of medication, but treatment tends to be longer, and surgery becomes a consideration if the tumor doesn’t shrink enough or causes compressive symptoms. The 60% macroprolactinoma rate in men is one reason male prolactinomas are often considered more clinically serious at the time of diagnosis, even though the underlying tumor type is the same.